298 studies found for:    nash
Show Display Options
Rank Status Study
21 Completed Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis (NASH)
Intervention: Drug: TRO19622
22 Active, not recruiting Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
Condition: Nonalcoholic Steatohepatitis
Interventions: Drug: GR-MD-02;   Drug: Placebo
23 Completed Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH)
Conditions: Non-alcoholic Steatohepatitis;   Fatty Liver
Interventions: Drug: Omega 3 Fish Oil supplements;   Drug: Placebo
24 Recruiting Open-Label Study To Evaluate Efficacy, Safety, Tolerability & PK of MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects
Conditions: Non-alcoholic Steatohepatitis;   Hypertriglyceridemia;   Non-alcoholic Fatty Liver Disease
Intervention: Drug: MN-001
25 Recruiting Prospective Cohort Assessing the Role of the Genotoxin Colibactin From Escherichia Coli B2 in the Genesis of NASH
Condition: Non-alcoholic Fatty Liver Disease
Interventions: Biological: liver biopsy;   Biological: collection of stools;   Biological: blood sample
26 Completed Effect of Metformin on Disease Progression in Patients With Cryptogenic Cirrhosis (NASH-related Cirrhosis) With Diabetes or Impaired Glucose Tolerance or Insulin Resistance
Condition: NASH Related Cirrhosis
Interventions: Drug: Metformin;   Drug: Insulin
27 Active, not recruiting Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Condition: Hypertension, Portal
Interventions: Drug: GR-MD-02;   Drug: Placebo
28 Completed
Has Results
Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH
Conditions: Nonalcoholic Steatohepatitis;   Liver Diseases
Interventions: Drug: Pentoxifylline;   Drug: Placebo
29 Recruiting Safety, Tolerability and Efficacy Study of 12 Weeks LJN452 Treatment in NASH Patients
Condition: Non-alcoholic Steatohepatitis
Interventions: Drug: LJN452;   Drug: Placebo
30 Recruiting Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis
Interventions: Drug: SHP626;   Drug: Placebo
31 Completed The Role of Leptin Receptors in NASH
Conditions: Nonalcoholic Steatohepatitis;   Metabolic Syndrome
Intervention: Other: no interventions, only regular blood-draw
32 Recruiting Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity
Condition: Obesity
Intervention: Drug: Metformin
33 Not yet recruiting EUS Guided Core Liver Biopsy and IGB Placement for the Diagnosis and Management of NASH and Obesity
Conditions: Obesity;   Non-Alcoholic Steatohepatitis
Interventions: Device: ORBERA Intragastric Balloon;   Procedure: Endoscopic Ultrasound Guided Core Liver Biopsy
34 Recruiting A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH
Condition: Fatty Liver
Intervention: Drug: Aramchol
35 Completed Omega 3 Supplementation in Fatty Liver
Condition: Fatty Liver
Intervention: Dietary Supplement: Omega 3
36 Active, not recruiting Efficacy and Safety Study of Cenicriviroc for the Treatment of NASH in Adult Subjects With Liver Fibrosis
Condition: Nonalcoholic Steatohepatitis
Interventions: Drug: Cenicriviroc;   Drug: Placebo
37 Terminated Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH
Condition: NASH (Non-alcoholic Steato-hepatitis)
Interventions: Drug: Rosiglitazone;   Drug: alpha-lipoic acid;   Drug: Rosiglitazone/alpha-lipoic acid
38 Not yet recruiting Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)
Condition: Nonalcoholic Steatohepatitis (NASH)
Interventions: Drug: GS-9674;   Drug: Placebo to match GS-9674
39 Recruiting Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)
Conditions: Non-alcoholic Fatty Liver Disease (NAFLD);   Non-alcoholic Steatohepatitis (NASH)
Interventions: Drug: AZ compound;   Other: Placebo
40 Active, not recruiting Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Drug: GS-4997;   Biological: SIM

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years